– USA, NY – Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company’s board of directors.
In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction valued at up to $600 million. Dr. Ulrich left Gilead in 2012 to help build Acerta Pharma as a member of the Board and as acting Chief Scientific Officer. In February of this year, AstraZeneca (NYSE:AZN) acquired a 55% share of Acerta Pharma for $4 billion with an option to purchase the remainder of the company for $3 billion.
Dr. Ulrich has many years of successful drug discovery and development experience. Prior to Acerta and Calistoga, Dr. Ulrich was senior scientific director with Merck Research Laboratories-Rosetta Inpharmatics (NYSE:MRK). Prior to Merck, Dr. Ulrich held various scientific and leadership positions within the pharmaceutical industry including Abbott Laboratories (now AbbVie, NYSE:ABBV), Pharmacia-Upjohn and The Upjohn Company, now part of Pfizer (NYSE:PFE). Prior to his pharmaceutical industry career, he worked at West Virginia and Michigan State Universities, and at Argonne National Laboratories. Dr. Ulrich has authored more than 125 publications and continues to serve on scientific and clinical advisory boards for industry, academia and government.
Dr. Ulrich received his B.A. in biology/chemistry and his M.A. in biomedical sciences from Western Michigan University. He received a Ph.D. in cellular and molecular biology from West Virginia University, and is a fellow of the Academy of Toxicological Sciences.
“We are honored to have Roger join our Board,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “He has achieved extraordinary success helping advance medicine, and is sure to be a tremendous asset as we move forward in achieving our mission of helping people afflicted with CNS-related edema to not only survive, but live life to the fullest.”
“I am very excited to join the Board of Remedy, said Roger Ulrich. “The company’s underlying science is transformative and I look forward to working with the board and the team to help shape what I’m certain to be its bright future.”
About Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, subarachnoid hemorrhage, and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.